
Vertex Gains EU Approval for ALYFTREK®, a New Daily Cystic Fibrosis Treatment
Vertex Secures EU Approval for ALYFTREK®, a New Once-Daily Treatment for Cystic Fibrosis Vertex Pharmaceuticals announced that the European Commission (EC) has approved ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who…